BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...design a bispecific antibody with a reduced risk of CRS and neurotoxicity. The company generated TNB-486...
...antibodies for those that induced CD19-targeted lymphoma destruction while minimizing cytokine release. In preclinical models, TNB-486...
Items per page:
1 - 1 of 1